about
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study.A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation.Saffron chemoprevention in biology and medicine: a review.Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.Unique pancreatic carcinoma cDNA found via subtracted libraries with limited normal tissue and tumor from the same patient.Superoxide dismutase (SOD) activity with Fe-chlorin e6-Na and suppression of malignant tumor growth in rats.Oxidative stress relief for cancer-bearing hosts by the protein-bound polysaccharide of Coriolus versicolor QUEL with SOD mimicking activity.Cancer clinical trials in the community setting: a 20 year retrospective.Leukemia after chemotherapy for cancer.Thymidine kinases: the enzymes and their clinical usefulness.Hormone receptor assays and their value in breast cancer therapy.Cytokines and the rational choice of immunological adjuvants.The clinical experience with interleukin-2 in cancer therapy.MHC-unrestricted immune surveillance of leukemia.Haplotype donor-generated graft-versus-leukemia responses: serendipity revisited.Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma. A phase II study.Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma.Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy.The impact of interleukin-2 on survival in renal cancer: a multivariate analysis.Rhabdoid tumor of the kidney in an adult: review of the literature and report of a case responding to interleukin-2.Whole body hyperthermia as a potential therapeutic option.Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies.Clinical and pharmacological study of intrahepatic artery infusion of thiotepa.In vitro cell-mediated immune responses induced by a polyvalent allogeneic melanoma vaccine.Inhibition of the growth of a murine and various human tumor cell lines in culture and in mice by mixture of certain substances of the circulatory system.Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus.In vitro effects of pentoxifylline and doxorubicin on cell survival and DNA damage in sensitive and MDR-P388 leukemia cells.Gene therapy for B-cell lymphoma in a SCID mouse model using an immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenovirus-polylysine conjugate.Enhancement of anti-cancer activity of cisdiaminedichloroplatinum by the protein-bound polysaccharide of Coriolus versicolor QUEL (PS-K) in vitro.A heavy-chain grafted antibody that recognizes the tumor-associated TAG72 antigen.Sensitization of P388 murine leukemia cells to epirubicin cytotoxicity by reserpine.Reversal of C1300 murine neuroblastoma multidrug resistance by cremophorEL, a solvent for cyclosporin A.The tyrosine residue at position 97 in the VH CDR3 region of a mouse/human chimeric anti-colorectal carcinoma antibody contributes hydrogen bonding to the TAG72 antigen.Chromosomal changes during the acquisition of resistance to adriamycin in tumorigenic human synovial cells.Binding, internalization and excretion of TGF alpha-dextran associated radioactivity in cultured human glioma cells.Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model.T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma.Improved delivery through biological membranes. LXI: Design, synthesis, and evaluation of a lipolol-based intradermal drug targeting system for 5-fluorouracil.The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center.
P1433
Q33490047-677A434F-AF98-4419-B10D-D1E135A356DFQ33490103-E743A5AD-D228-4DA4-A6DB-8975585B30E5Q34058414-C0D99D3A-CB51-4530-9C4C-321139B68496Q34062338-9E69723B-BA76-44D3-B0CB-E5D9EF29F09CQ34722039-24D7B3D9-B2AB-409E-B67E-8FFB9CE56CC1Q36711341-8A816CC0-A8E7-4E45-966E-E5BADFD6D990Q39479049-0283D787-7D2B-44C4-8899-65D29B0F213EQ39488754-BD5F3528-98C6-40D0-B1AC-CB2E14C15AC8Q40476173-3833277A-DD1B-4A61-A551-A9ADEC29F458Q40558548-1D8103BD-33B8-434B-8531-BAA2C68B1C1FQ40558554-7827565E-1BC7-4B1B-B2AA-7E52E537DD39Q40563688-F31D7C8D-F58F-471D-A5B2-C7D18045E660Q40563694-96597758-2448-4DCF-B39F-FD871F5AAC98Q40568453-670A9CC9-D5E7-4B4B-8FB2-ABC5B89820ACQ40568459-BB799AF6-EB84-4545-A765-0F56DDAFAD9FQ40690748-28CF9BA0-7F6A-4FF6-BE85-4B8A5FCD781AQ40691488-E86B07A5-B10C-4F88-BFA0-C5F05531CD60Q40691493-1C1EB7BD-38B0-48BE-ACAD-CB69E8798E0EQ40708713-AC4E6DB9-064A-4342-A08D-3F001D41610EQ40725424-4B6FF9D1-9459-4A1E-8CA8-DA38EE7DF0B8Q40938871-A86C16CD-7812-4A7E-93D2-1FD78CD1DD53Q40963546-6EA7FD85-59E8-4F72-B822-3102F111F398Q41055451-6D3C51DD-91D0-4C14-9B54-A78C02FD7C4EQ41099321-65C290D0-B132-49AB-82C4-238AC4E8F591Q41387377-24612B89-3AF9-4F60-9115-A0DDC776EA32Q41398176-F9920567-0259-4BAB-B9B8-6ABC338CE6ABQ41504382-0AD8323C-EE19-4BC4-BB6F-0D1DB190D1C3Q41504504-D4365231-BE4D-4BA9-9442-521D5CE918AEQ41504514-C609AE46-89CF-4282-98A1-5C8AFD090E02Q41505584-999EB117-CDAD-44BB-972F-324326EDFC66Q41505589-3BFAA366-4354-4597-9435-51D742C42F98Q41587094-92C29E5B-9A78-4F6E-9AF9-73844DD59166Q41587099-9CA60289-8333-4BD9-BD4D-F80165F3CC6CQ41587111-25254C53-32E7-429F-B579-3EEDBE87F0BBQ41587120-362A35E3-E782-41B2-8D30-041A2E1914E9Q41588448-E0C2601C-C9C7-4D61-8624-4956014ADFD9Q43407443-EF016781-08BD-47E1-B2DB-153F6CE15586Q44553719-42E267DB-401C-45F1-BABE-9F5B0D6295BDQ46453751-6C0C71B8-2E12-48DE-ABB6-40DC3BF84AD5Q46769659-57584DAB-5DBA-48B7-A66C-FEFA245A1E9A
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Mary Ann Liebert, Inc.
@nl
wissenschaftliche Fachzeitschrift
@de
name
Cancer biotherapy
@ast
Cancer biotherapy
@en
Cancer biotherapy
@es
Cancer biotherapy
@it
Cancer biotherapy
@nl
type
label
Cancer biotherapy
@ast
Cancer biotherapy
@en
Cancer biotherapy
@es
Cancer biotherapy
@it
Cancer biotherapy
@nl
altLabel
Cancer Biother
@en
Cancer Biother.
@en
prefLabel
Cancer biotherapy
@ast
Cancer biotherapy
@en
Cancer biotherapy
@es
Cancer biotherapy
@it
Cancer biotherapy
@nl
P3181
P1055
P1156
P1476
Cancer biotherapy
@en